Larry Fish, MD
Ophthalmology · Dallas, TXNPI 1699728386
Payments from drug & device makers
Across 172 payments — averaging $191.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$27K
- Lumibird Medical Inc.$2K
- Alcon$1K
- AbbVie$976
- Johnson & Johnson Surgical Vision, Inc.$483
- Novartis$342
- plus $2K from 16 others
Across 1 payment — averaging $15.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$16
What the payments were for
- Speaking & faculty fees$1,52623%
- Food & beverage$4,97777%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 23 | $26,577 |
| Lumibird Medical Inc. | 1 | $1,500 |
| Alcon | 28 | $1,061 |
| AbbVie(2 entities) | 41 | $976 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $483 |
| Novartis | 16 | $342 |
| Biotissue Holdings Inc. | 4 | $297 |
| Sun Pharmaceutical Industries Inc. | 9 | $236 |
| Rxsight Inc | 7 | $233 |
| Tarsus Pharmaceuticals, Inc. | 5 | $206 |
| Harrow Eye, LLC | 5 | $192 |
| Bausch & Lomb Americas Inc. | 8 | $180 |
| Oyster Point Pharma, Inc. | 3 | $163 |
| Alcon Research LLC | 1 | $134 |
| Aerie Pharmaceuticals, Inc. | 6 | $115 |
| Johnson & Johnson Vision Care, Inc. | 3 | $89 |
| Thea Pharma Inc. | 2 | $38 |
| Astellas Pharma US Inc | 1 | $32 |
| Rayner Intraocular Lenses Limited | 1 | $30 |
| Shire North American Group Inc | 1 | $22 |
| Amgen | 1 | $21 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tango-R SLT/YAG Combination Laser with Reflex Technology$1,500
- Prokera$269
- AmnioGraft$269
- DAILIES$252
- CATALYS SYSTEM$136
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$131
- TYRVAYA$129
- XDEMVY$128
- Tecnis Symfony IOL$122
- Tecnis Multifocal Family of 1-piece IOLS$122
- Tecnis Toric 1-piece IOL$122
- VEVYE$120
- Wavelight Sightmap$116
- LUMIGAN$112
- DURYSTA$111
- CEQUA$102
- RESTASIS$100
How this compares
$32,942 in reported general payments places this provider in the 85th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 334 | $194,049 |
| CombiganBrimonidine Tartrate/Timolol | 134 | $62,021 |
| RocklatanNetarsudil Mesylat/Latanoprost | 69 | $52,040 |
| XdemvyLotilaner | 17 | $33,321 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 184 | $32,223 |
| XiidraLifitegrast | 20 | $31,868 |
| Alphagan PBrimonidine Tartrate | 73 | $30,173 |
| RestasisCyclosporine | 20 | $28,026 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 79 | $18,424 |
| VyzultaLatanoprostene Bunod | 38 | $17,530 |
| RhopressaNetarsudil Mesylate | 23 | $15,442 |
| Brimonidine Tartrate | 455 | $12,833 |
| Latanoprost | 964 | $11,677 |
| Travoprost | 45 | $6,902 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 440 | $5,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $976 | $314,270561 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $115 | $67,48292 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $180 | $49,39758 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $206 | $33,32117 claims |
| AlconSimbrinza | $1,061 | $18,42479 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Besivance | $14 | $5,24434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Dallas
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Jeffrey WhitmanDallas$1.7M
- Oluwatosin SmithDallas$1.7M
- Davinder GroverDallas$1.3M
- Robert WangDallas$594K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.